A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-α in anemic patients with low-risk MDS

[1]  M. Delforge,et al.  A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes , 2017, Leukemia.

[2]  H. Deeg,et al.  Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. , 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

[3]  G. Mufti,et al.  Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  A. Ganser,et al.  Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study , 2014, European journal of haematology.

[5]  P. Vyas,et al.  Guidelines for the diagnosis and management of adult myelodysplastic syndromes , 2014, British journal of haematology.

[6]  M. Cazzola,et al.  Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. , 2013, Blood.

[7]  G. Barosi,et al.  Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines. , 2010, Leukemia research.

[8]  D. Cella,et al.  Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996). , 2009, Blood.

[9]  L. Malcovati,et al.  Clinical relevance of extra-hematologic comorbidity in the management of patients with myelodysplastic syndrome , 2009, Haematologica.

[10]  J. Reeves,et al.  Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. , 2008, Blood.

[11]  David P Steensma,et al.  Are myelodysplastic syndromes "cancer"? Unexpected adverse consequences of linguistic ambiguity. , 2006, Leukemia research.

[12]  R. Tehranchi.  Impact of growth factors in the regulation of apoptosis in low-risk myelodysplastic syndromes , 2006, Medical oncology.

[13]  I. Dybedal,et al.  Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF. , 2005, Blood.

[14]  I. Dybedal,et al.  Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF. Commentary , 2005 .

[15]  R. Latagliata,et al.  Impact of a new dosing regimen of epoetin alfa on quality of life and anemia in patients with low-risk myelodysplastic syndrome , 2005, Annals of Hematology.

[16]  Nikolaos Laoutaris,et al.  Prolonged administration of erythropoietin increases erythroid response rate in myelodysplastic syndromes: a phase II trial in 281 patients , 2002, British journal of haematology.

[17]  B. Cheson,et al.  Report of an international working group to standardize response criteria for myelodysplastic syndromes. , 2000, Blood.

[18]  V. Diehl,et al.  Treatment of anaemia in myelodysplastic syndromes with prolonged administration of recombinant human granulocyte colony‐stimulating factor and erythropoietin , 2000, British journal of haematology.

[19]  N. Piva,et al.  A randomized double‐blind placebo‐controlled study with subcutaneous recombinant human erythropoietin in patients with low‐risk myelodysplastic syndromes , 1998, British journal of haematology.

[20]  P. Greenberg,et al.  Erythroid response to treatment with G‐CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model , 1997, British journal of haematology.

[21]  L. Lessin,et al.  The use of r‐HuEpo in the treatment of anaemia related to myelodysplasia (MDS) , 1995, British journal of haematology.

[22]  W. Vainchenker,et al.  Effects of granulocyte-macrophage colony-stimulating factor and erythropoietin on leukemic erythroid colony formation in human early erythroblastic leukemias. , 1987, Blood.